## ICUI: ICU Medical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.2% below STRENGTH zone (4.0-10.0%); PEG 1.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (47% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($139.67)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. ICU Medical (ICUI): Reassessing Valuation After Weak Growth, Margin Pressures and Investor Concern**
- Source: Simply Wall Street | 20251225T140844 | Somewhat-Bullish | Relevance: 100%
- ICU Medical (ICUI) is facing investor concerns due to weakening sales and shrinking free cash flow margins, despite a recent 24.3% share price rebound over three months. The company is considered 18.7% undervalued with a fair value near $181, driven by anticipated margin rebuild, cash flow renewal, and earnings growth following manufacturing network consolidations and integration synergies from the Smiths Medical acquisition. However, persistent tariff headwinds and ongoing integration costs could pose risks to this positive outlook.

**2. Programmable Infusion Pumps And Catheters Market 2025- 2032**
- Source: openPR.com | 20251226T120917 | Somewhat-Bullish | Relevance: 88%
- This report from Coherent Market Insights details the Programmable Infusion Pumps And Catheters Market from 2025 to 2032, highlighting key insights, segmentation, and growth opportunities. It covers strategic investment hotspots, regional trends, and profiles major industry players like ICU Medical, Inc., Smiths Group plc., and Baxter International Inc. The study provides a comprehensive analysis of market structure, performance, and future developments, aiding decision-makers in navigating the evolving landscape.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.3% (-1.2%)
- Vanguard Group Inc: 10.6% (-1.3%)
- Janus Henderson Grou: 10.0% (+0.1%)
- Fuller & Thaler Asse: 5.6% (-0.3%)
- JPMORGAN CHASE & CO: 5.5% (+78.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +1.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.70 elevated, pricing in significant growth expectations. Forward P/E 18.5x stretched relative to 6% growth. Balance sheet: strong liquidity (2.5x). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.7B |
| Beta | 0.83 |
| 52W Range | $107.00 - $175.51 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.70 |
| Forward P/E | 18.5 |
| Current P/E | 19.6 |
| YoY Growth | 6.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -1.1% to 0.2% (+1.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.8pp (needs >4.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.54), momentum weakening. RSI neutral at 60. Volume at 47% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.23% (CS: 56) | Neutral |
| RSI_14 | 59.8 | Neutral |
| MACD Histogram | -0.54 | Bearish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.082x | Above |
| vs SMA200 | 1.114x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $147.87
- **Stop Loss:** $139.67 (5.5% risk)
- **Target:** $156.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 160
- **Position Value:** $23,659.20
- **Portfolio %:** 23.66%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-26 (Est: $1.69)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $2.03 | +41.6% |
| 2025Q2 | $1.50 | $2.10 | +40.0% |
| 2025Q1 | $1.28 | $1.72 | +34.4% |
| 2024Q4 | $1.48 | $2.11 | +42.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*